Loading clinical trials...
Loading clinical trials...
A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions
Interventions
Copanlisib
Niraparib
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
April 29, 2019
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
March 11, 2026
NCT06399757
NCT07077876
NCT03660826
NCT05824481
NCT00977574
NCT03460483
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions